High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer

Virchows Archiv

Volumn 463, Issue 5, 2013, Pages 681-687

  Choi, Jung Woo ^a   Kim, Younghye ^a   Lee, Ju Han ^a   Kim, Young Sik ^a  

^a Korea University   (South Korea)

Author keywords

CDC20; MAD2; Spindle assembly checkpoint; Urothelial carcinoma

Indexed keywords

CELL CYCLE PROTEIN 20; PROTEIN MAD2;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; M PHASE CELL CYCLE CHECKPOINT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STAINING; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; CDC20 PROTEINS; CELL CYCLE; CELL CYCLE CHECKPOINTS; FEMALE; HUMANS; MAD2 PROTEINS; MALE; MIDDLE AGED; MITOSIS; PROGNOSIS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84889089838     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1473-6     Document Type: Article

References (23)

1. Knowles MA (2006) Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27(3):361-373. doi: 10.1093/carcin/bgi310
2. Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9(7):882-895. doi: 10.1101/gad.9.7.882
3. Florl AR, Schulz WA (2008) Chromosomal instability in bladder cancer. Arch Toxicol 82(3):173-182. doi: 10.1007/s00204-008-0280-3
4. Bharadwaj R, Yu H (2004) The spindle checkpoint, aneuploidy, and cancer. Oncogene 23(11):2016-2027. doi: 10.1038/sj.onc.1207374
5. Kim S, Yu H (2011) Mutual regulation between the spindle checkpoint and APC/C. Semin Cell Dev Biol 22(6):551-558. doi: 10.1016/j.semcdb.2011.03.008
6. Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H (2012) Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 5:15. doi: 10.1186/1756-8722-5-15
7. Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M (2012) Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol 106(4):423-430. doi: 10.1002/jso.23109
8. Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S (2007) Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28(1):81-92. doi: 10.1093/carcin/bgl100
9. Wang L, Yin F, Du Y, Du W, Chen B, Zhang Y, Wu K, Ding J, Liu J, Fan D (2009) MAD2 as a key component of mitotic checkpoint: a probable prognostic factor for gastric cancer. Am J Clin Pathol 131(6):793-801. doi: 10.1309/AJCPBMHHD0HFCY8W
10. Zhang SH, Xu AM, Chen XF, Li DH, Sun MP, Wang YJ (2008) Clinicopathologic significance of mitotic arrest defective protein 2 overexpression in hepatocellular carcinoma. Hum Pathol 39(12):1827-1834. doi: 10.1016/j.humpath. 2008.06.003
11. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, Matsuda K (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27(11):1562-1571. doi: 10.1038/sj.onc.1210799
12. Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA (2011) Identification of common differentially expressed genes in urinary bladder cancer. PLoS One 6(4):e18135. doi: 10.1371/journal.pone.0018135
13. Schvartzman JM, Duijf PH, Sotillo R, Coker C, Benezra R (2011) Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer Cell 19(6):701-714. doi: 10.1016/j.ccr.2011.04.017
14. Edge SB (ed) (2010) AJCC Cancer staging manual, 7th edn. Springer, Chicago
15. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours, vol 6. IARC Press, Lyon
16. Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W (2009) Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 8:8. doi: 10.1186/1476-4598-8-8
17. Howell BJ, Hoffman DB, Fang G, Murray AW, Salmon ED (2000) Visualization of Mad2 dynamics at kinetochores, along spindle fibers, and at spindle poles in living cells. J Cell Biol 150(6):1233-1250. doi: 10.1083/jcb.150.6.1233
18. Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, Kay EW, O'Leary J, McCann A (2012) Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. J Pathol 226(5):746-755. doi: 10.1002/path.3035
19. Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK (2000) Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 101(6):635-645. doi: 10.1016/S0092-8674(00)80875-2
20. Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, Lowe SW, Benezra R (2007) Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11(1):9-23. doi: 10.1016/j.ccr.2006.10.019
21. Kabeche L, Compton DA (2012) Checkpoint-independent stabilization of kinetochore-microtubule attachments by Mad2 in human cells. Curr Biol 22(7):638-644. doi: 10.1016/j.cub.2012.02.030
22. Sharma N, Dey P (2011) Cell cannibalism and cancer. Diagn Cytopathol 39(3):229-233. doi: 10.1002/dc.21402
23. Krajcovic M, Johnson NB, Sun Q, Normand G, Hoover N, Yao E, Richardson AL, King RW, Cibas ES, Schnitt SJ, Brugge JS, Overholtzer M (2011) A non-genetic route to aneuploidy in human cancers. Nat Cell Biol 13(3):324-330. doi: 10.1038/ncb2174